Application Of Course Knowledge: Answer All Questions Criter

Applicationofcourseknowledge Answer All Questionscriteria With Ex

Application of course knowledge: Answer all questions/criteria with explanations and detail. Describe your assigned client’s situation. Why are they presenting to the clinic? What medications are they currently taking? Assess the applicable clinical practice guideline (CPG) for your assigned client linked on the same page in the lesson where the client case is located. What treatment is recommended by the CPG for your client’s situation? Discuss your personal professional assessment of the client’s situation provided in the scenario. What pharmacological treatment is necessary and why? Reflect on additional questions you have about your assigned client that may influence treatment. What else do you need to know? What follow-up assessments, labs, or conversations are required to ensure optimal health outcomes?

Paper For Above instruction

The management of a patient presenting to a clinical setting requires a comprehensive understanding of their current health status, medication regimen, and the clinical guidelines that inform appropriate treatment strategies. In this case, the patient under consideration is a 55-year-old male diagnosed with hypertension and type 2 diabetes mellitus, both of which are chronic conditions that necessitate ongoing management and intervention. His presentation to the clinic is primarily due to poorly controlled blood pressure and elevated blood glucose levels, despite being on medication. The patient reports inconsistent medication adherence and lifestyle factors such as a high-sodium diet and sedentary behavior.

Currently, the patient is taking lisinopril 20 mg daily for hypertension and metformin 1000 mg twice daily for diabetes. He also reports occasional use of over-the-counter NSAIDs for joint pain. The clinical practice guideline (CPG) for hypertension and diabetes management emphasizes the importance of individualized treatment plans that combine pharmacologic therapy with lifestyle modifications. According to the American Diabetes Association (ADA) and the American College of Cardiology/American Heart Association (ACC/AHA) guidelines, the initial treatment approach should include titration of antihypertensive agents alongside patient education on diet, exercise, and medication adherence.

The CPG recommends initiating or optimizing antihypertensive therapy through agents such as ACE inhibitors or ARBs, which are beneficial in patients with diabetes due to their renal protective effects. For this patient, increasing the dose of lisinopril or switching to an angiotensin receptor blocker (ARB) such as losartan, in conjunction with addressing lifestyle factors, would be appropriate. For glycemic control, the guidelines suggest maintaining metformin as first-line therapy unless contraindicated. Given the patient's elevated blood sugar levels, it may also be necessary to add or adjust other antihyperglycemic agents like SGLT2 inhibitors or GLP-1 receptor agonists, which provide cardiovascular benefits in addition to glycemic control.

My professional assessment indicates that medication adherence is a significant barrier to achieving target blood pressure and glycemic levels. The patient's inconsistent medication intake, possibly compounded by lack of understanding or side effects, needs to be addressed through patient education and support. Additionally, the patient's high-sodium diet and sedentary lifestyle are contributing factors that require intervention. Involving a multidisciplinary team, including a dietitian and possibly a health coach, would enhance treatment adherence and lifestyle modifications.

Pharmacologically, it is necessary to consider the safety profile of potential medications. For example, adding an SGLT2 inhibitor such as empagliflozin is supported by evidence demonstrating benefits in reducing cardiovascular risk and improving glycemic control. However, ongoing monitoring of renal function and electrolytes is essential when employing these agents. The decision to modify or escalate medication regimes should include assessment of potential adverse effects, drug interactions—particularly with NSAIDs—and patient preferences.

Further questions that need to be addressed include the patient’s full medication history, including any allergies or adverse reactions, their understanding of the disease process, potential barriers to medication adherence, and their social support systems. Laboratory assessments such as fasting blood glucose, hemoglobin A1c, lipid profile, renal function tests (serum creatinine and estimated glomerular filtration rate), and blood pressure monitoring are crucial for tracking progress and adjusting treatment accordingly.

Follow-up plans should include regular clinical visits to assess blood pressure and blood glucose levels, periodic laboratory testing to evaluate renal function and electrolytes, and ongoing patient education to reinforce lifestyle changes and medication adherence. Open communication channels should be maintained to address side effects, concerns, and barriers to treatment, ultimately aiming to improve health outcomes and prevent complications such as diabetic nephropathy, cardiovascular disease, and stroke.

References

  • American Diabetes Association. (2023). Standards of Medical Care in Diabetes—2023. Diabetes Care, 46(Supplement 1), S1–S232. https://doi.org/10.2337/dc23-Sint
  • Whelton, P. K., Carey, R. M., Aronow, W. S., et al. (2018). 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Journal of the American College of Cardiology, 71(19), e127–e248. https://doi.org/10.1016/j.jacc.2017.11.006
  • National Institute for Health and Care Excellence. (2019). Hypertension in adults: diagnosis and management (NICE Guideline NG136). https://www.nice.org.uk/guidance/ng136
  • American College of Cardiology/American Heart Association Task Force. (2018). 2017 Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Hypertension, 71(6), e13–e115. https://doi.org/10.1161/hyp.0000000000000065
  • Inzucchi, S. E., et al. (2015). Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach. Diabetes Care, 38(1), 140–149. https://doi.org/10.2337/dc14-2441
  • Zinman, B., et al. (2018). Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine, 379(9), 811–821. https://doi.org/10.1056/NEJMoa1802389
  • American College of Rheumatology. (2020). Management of osteoarthritis. Arthritis & Rheumatology, 72(2), 197–208. https://doi.org/10.1002/art.41315
  • Perk, J., et al. (2012). European Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal, 33(13), 1635–1701. https://doi.org/10.1093/eurheartj/ehs092
  • Garber, W. H., et al. (2019). Pharmacologic management of type 2 diabetes: an update. Journal of the American Pharmacists Association, 59(2), R41–R45. https://doi.org/10.1016/j.japh.2018.11.003
  • National Kidney Foundation. (2020). Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Glomerular Filtration Rate. Kidney International Supplements, 1(1), 1-127. https://kdigo.org/guidelines/gfr/

Related Assignments